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a b s t r a c t
The need to assess the risk from food allergens derives directly from the need to manage effectively this
food safety hazard. Work spanning the last two decades dispelled the initial thinking that food allergens
were so unique that the risk they posed was not amenable to established risk assessment approaches and
methodologies. Food allergens possess some unique characteristics, which make a simple safety assess-
ment approach based on the establishment of absolute population thresholds inadequate. Dose distribu-
tion modelling of MEDs permitted the quantification of the risk of reaction at the population level and has
been readily integrated with consumption and contamination data through probabilistic risk assessment
approaches to generate quantitative risk predictions. This paper discusses the strengths and limitations of
this approach and identifies important data gaps, which affect the outcomes of these predictions. These
include consumption patterns among allergic individuals, analytical techniques and their application,
severity-dose relationships, and the impact of extraneous factors which alter an individual’s physiology,
such as infection or exercise. Nevertheless, application of these models has provided valuable insights,
leading to further refinements and generating testable hypotheses. Their application to estimate the risk
posed by the concurrent consumption of two potentially contaminated foods illustrates their power.
 2014 ILSI Europe. Published by Elsevier Ltd. All rights reserved.
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1. Introduction
The need to assess the risk from allergenic constituents or
residues in manufactured food products arose very soon after food
allergy was identified as a public health issue and mandatory food
allergen source labelling as well as voluntary precautionary
allergen statements on products ensued. It became apparent that
failure to assess risk would lead to excessive warnings of unin-
tended allergen presence on products and reduced food choices
for people with food allergy. A pioneering piece of work demon-
strated the feasibility of conducting allergen risk assessments
when it showed to a standard higher than that required of hypoal-
lergenic formulae that highly refined (N/RBD) peanut oil did not
trigger reactions in people with peanut allergy, whereas crude pea-
nut oil, which contained up to 100 times more protein, could do so
(Hourihane et al., 1997a).
However, assessing the risk arising from the presence of aller-
genic constituents in products remained challenging. Initially the
question was raised whether allergic reactions even obeyed classi-
cal toxicological principles, such as dose–response relationships.
As data built up on reactivity within populations of people with
food allergies (Taylor et al., 2004), it became clear that the range
of reactivity to allergens is extremely wide, spanning at least 6 or-
ders of magnitude, based on the results of controlled food chal-
lenge studies. The lack of knowledge about the distribution of
this reactivity added to the perception generated by anecdotal case
reports that most reactions occurred in response to extremely
small amounts that would be difficult to measure, let alone man-
age in ordinary food manufacturing facilities.
Over the last decade or so, much progress has been made in fill-
ing a number of the data and knowledge gaps that prevented an
adequate assessment of the risk. Food challenge data from studies
designed to identify and characterise low dose reactors have be-
come available in sufficient quantity to derive dose distributions
for a large number of the more significant allergenic constituents.
These data, on their own, would have been of much more limited
value if the tools to analyse them had also not developed in paral-
lel. Thus statistical modelling of dose distributions has become a
widely accepted approach to characterising allergenic hazard
(Bindslev-Jensen et al., 2002; Crevel et al., 2007). Similarly, proba-
bilistic approaches to estimating the likely consequences of a par-
ticular pattern of allergen contamination are gaining currency
(Spanjersberg et al., 2007), although gaps remain. These include
inadequate data to characterise the hazard with confidence for
some allergenic foods, but perhaps the most significant is under-
standing the background frequency of reactions that occur from
day to day among allergic consumers and the associated pattern
of severity. This background will in part be influenced by the food
choices of allergic consumers (e.g. avoidance of certain food types,
brands, etc.) and their acceptance of certain types of reaction (e.g.
the milder variety). Inadequate knowledge about these food
choices together with limited understanding of the frequency
and range of product contamination point to an important data
gap around the exposure component of the risk posed by food
allergens.
Notwithstanding the remaining data and knowledge gaps, the
progress to date, as well as initiatives such as the Allergen Bureau’s
of Australia and New Zealand VITAL initiative, demonstrated that
allergen management could be placed on a sounder, evidence-
based footing, based on robust risk assessment. This would
improve the safety of allergic consumers, while providing the food
industry with a clear set of standards towards which they could
work. This paper presents the results of the work by the ILSI-
Europe Food Allergy Task Force’s Expert Group and the discussions
with stakeholders concerning risk assessment of allergenic foods.
2. Evolution of risk assessment for food allergens
Allergens in food pose a health risk to humans who may be-
come sensitised or are already sensitised to these proteins. Termi-
nologies and methodologies for food risk and safety assessment
and management developed and evolved largely in response to
the threats to public health from chemical or microbiological con-
taminants that may be present in food. For a long time, it was ques-
tioned whether classical toxicological risk assessment principles
could be applied to allergy and allergenic foods. However, with
better understanding of reactions to allergens, together with
increasing volumes and quality of data, it is now widely accepted
that the broad principles and approaches of chemical toxicology
risk assessment can be applied to food allergens (Madsen et al.,
2009; Spanjersberg et al., 2007, 2010), as can the same terminolo-
gies and methodologies. This section describes the concepts and
terminology in (mainly chemical) food safety and risk assessment
and their applicability to allergens. In addition, practical ap-
proaches that have been developed for food allergen risk assess-
ment are described.
2.1. Concepts and terminology in risk assessment for foods
Clarity of thought and communication among risk assessors and
managers are critical in ensuring good management of risk and
much effort has been expended on international harmonisation
of terminologies. In this paper, terminology is based on definitions
set out by the INTERNATIONAL PROGRAMME ON CHEMICAL
SAFETY (IPCS) in 2009 in their ‘‘Alphabetical list of selected key
generic terms in hazard and risk assessment and their definitions’’
(INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY HARMONI-
ZATION PROJECT). This terminology has been harmonised across
the different disciplines covered by the Codex Alimentarius Com-
mission and thus also applies to microbiological risk assessment
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for foods, to which risk assessment for allergens also bears a num-
ber of similarities (Codex Alimentarius Commission, 1999b).
Allergens, like chemicals and microorganisms, may pose a risk
to human health due to their inherent properties, otherwise known
as the hazard and specifically defined as: an inherent property of an
agent or situation having the potential to cause adverse effects when
an organism, system, or (sub)population is exposed to that agent.
The probability of an adverse effect in an organism, system, or
(sub)population caused under specified circumstances by exposure
to an agent is called risk. A concept closely linked to risk is safety.
Safety may have various (legal or societal) definitions, of which one
is the practical certainty that significant adverse effects will not re-
sult from exposure to an agent under defined circumstances. It can
also be represented as the reciprocal of risk and may also be per-
ceived as a risk that society accepts.
Risk analysis is the overall process for controlling situations
where an organism, system, or (sub)population could be exposed
to a hazard. The risk analysis process consists of three components:
risk assessment, risk management, and risk communication.
Risk assessment describes the process through which is
estimated the risk to a given target organism, system, or (sub)pop-
ulation, including the identification of attendant uncertainties,
following exposure to a particular agent, taking into account the
inherent characteristics of the agent of concern as well as the char-
acteristics of the specific target system including the (sub)popula-
tion. It includes four steps: hazard identification, hazard
characterization, exposure assessment, and risk characterization.
Hazard identification can refer to the determination that a sub-
stance with hazardous properties is present, but is more generally
meant as the identification of the type and nature of the adverse
effects that an agent can cause and as such its inherent capacity
to cause these in an organism, system, or (sub)population. In
hazard characterization, a qualitative and, wherever possible,
quantitative description of the inherent property of an agent or sit-
uation having the potential to cause adverse effects is made, to-
gether with its relationship to dose, where possible. Hazard
identification and hazard characterization together constitute haz-
ard assessment.
The hazard assessment findings can be used to derive safe levels
of exposure, for instance through the elaboration of a Reference
Dose, a term which IPCS uses to describe the daily dose that is
likely to be without deleterious effect even if continued exposure
occurs over a lifetime. An example of a Reference Dose is the
Acceptable Daily Intake (ADI): the estimated maximum amount
of an agent to which individuals in a (sub)population may be
exposed daily over their lifetimes without appreciable health risk.
Often, a Reference Dose or ADI is used as a basis for calculating
maximum tolerable levels of substances in food. Many food safety
standards have been set through this process of assessing hazard
data and establishing a Reference Dose and a maximum level for
food.
Since dose is a parameter critical to the risk posed by a sub-
stance, exposure assessment forms an essential part of determin-
ing whether the hazardous properties of a substance will
translate to adverse health effects. Results of an exposure assess-
ment can be directly compared with an established assessment
of the hazard information that resulted in a Reference Dose or
established maximum level in food. An exposure at or below the
Reference Dose or maximum level is assumed to be safe. In cases
where past, current or expected exposure is in excess of a Refer-
ence Dose or maximum level, or in cases where a reference Dose
or maximum level has not been established, a risk characterization
may be performed to calculate or estimate the risk. The risk
characterization may be defined as the qualitative and, wherever
possible, semi-quantitative or quantitative determination, includ-
ing attendant uncertainties, of the probability that known and
potential adverse effects of an agent will occur in a given organism,
system, or (sub)population, under defined exposure conditions.
A risk assessment may lead to the conclusion that the risk needs
to be mitigated, in which case a risk management phase will fol-
low, together with communication of that risk, as appropriate.
2.2. Application of general concepts and terminology to food allergen
risk assessment
Assessing the risk from allergens does not fundamentally differ
from assessing the risk from chemical substances or microbiologi-
cal agents, although there are clearly distinct features associated
with each. Thus some aspects of allergen risk assessment resemble
those pertaining to chemical substances, while others share paral-
lels with microbiological agents. This may be best illustrated by
considering each of the steps.
2.2.1. Hazard identification
For foods that are already commonly consumed, hazard identi-
fication occurs retrospectively through case reports, rather than
prospectively, through predictive toxicological tests. Thus a food
is identified as allergenic, because individuals are reported to react
to it in a manner consistent with allergic reactions mediated by IgE
antibodies. Hazard identification is then ultimately completed by
demonstration of IgE binding to individual proteins in the food
and confirmatory tests including clinical controlled oral challenges
in affected individuals. Therefore, in allergies to commonly con-
sumed foods, the hazard of concern is the ability to elicit reactions
in sensitised individuals, rather than the ability to sensitise in the
first instance. Currently, unlike most food chemicals, there are no
validated animal models to assess the toxicity of food allergens;
thus, only reactions in sensitised individuals can be considered
adequate confirmation that a food is an allergenic hazard in hu-
mans. Hazard identification therefore relies completely on human
data from previously exposed and sensitised individuals, resem-
bling microbiological hazard identification, which relies principally
on epidemiological and surveillance data rather than prospective
studies in animals.
2.2.2. Hazard characterisation
Hazard characterisation for allergens arguably possesses advan-
tages compared to characterisation of both chemical and microbio-
logical hazards. As it relies on human data, animal to man
extrapolation of the results of toxicological studies and consider-
ation of various other qualitative and quantitative uncertainties
associated with non-human toxicity data are unnecessary. This
constitutes a distinct advantage for food allergen risk assessment
compared to traditional chemical risk assessment. However, the
need for human data also imposes ethical and practical constraints
that limit both the amount and type of data that can be generated.
Challenge studies rely on volunteer participants who can only be
tested a limited number of times and furthermore may not be fully
representative of the whole population allergic to a food. The avail-
ability of suitable clinics and trained personnel, as well as the prev-
alence of allergy to a particular food further limit the numbers that
can be tested. Detailed assessment of the relationship between the
dose and the response must comply with the requirements not to
harm the individuals under investigation. Because of the risks
posed and the ethical considerations, deliberate administration of
microbiological agents to investigate dose response relationships
is rare, whereas with food allergens it can be included as part of
the diagnostic protocol since the information obtained is useful to
the individuals involved as well as from a population perspective.
Thus food allergen hazard can be much more accurately character-
ised. Notwithstanding the limitations inherent in human studies,
increasing amounts of data of ever better quality continue to
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become available on the relationship between minimum eliciting
dose and frequency of reaction in the population allergic to a num-
ber of priority allergens. These data demonstrate also that thresh-
olds for the elicitation of allergic effects by food allergens exist at
an individual level and thus also at a population level. Depending
on the risk management questions and the goal, focus and approach
of the risk assessment, uncertainty factors may be applied. Probabi-
listic modelling (see subsection 5.1), takes account of the uncer-
tainty and variability associated with each input variable and
therefore negates the need to apply, often arbitrary, uncertainty
factors to the risk assessment output. This is another potential
advantage compared to traditional chemical risk assessments.
2.2.3. Intake (exposure) assessment
In principle, this step does not differ in any significant way from
that required for chemical risk assessment. However, the exposure
metric for food allergens is the amount consumed on a single eat-
ing occasion, or within a relatively short period of time, rather than
long-term exposure as with chemical exposure assessment. The
exposure assessment for allergens therefore resembles much more
closely microbiological exposure assessment inasmuch as the fo-
cus is on short-term acute effects rather than long-term effects
(Codex Alimentarius Commission, 1999b). Yet, important differ-
ences remain. These include the need to take account of the growth
of microorganisms at different stages and the fact that the risk
assessment for food allergens, unlike for chemical contaminants
or microorganisms in general, focusses on a relatively small sub-
population, a high proportion of which are aware of the presence
of specific hazards in food that may pose a risk to them: allergens.
Their patterns of food consumption might therefore differ from
that of the general population. This could affect their total expo-
sure and therefore risk, either decreasing it or increasing it depend-
ing on the product. It may be assumed, but this is yet to be
confirmed, that differences in food choice will be larger than differ-
ences in the amounts of certain food products consumed by aller-
gic and non-allergic users. In other words, allergic and non-allergic
consumers of a food will consume a broadly similar amount on
each eating occasion. To the best of our knowledge, no structured
broad (nationwide) studies have been conducted that address this
factor, although the MIRABEL study in France will begin to yield in-
sights in the near future (Nguyen-Grosjean, 2013). Also lacking are
any structured surveys into the distribution of specific allergens
present by cross-contact in the general food supply, a situation
made worse by the limitations of current tools. This hampers the
translation of food consumption data into allergen intake data.
2.2.4. Risk characterisation
The final step in the allergen risk assessment process also needs
to be applied in a manner adapted to the limitations in knowledge
and data, as well as to the different circumstances associated with
allergenicity discussed above. A risk assessment needs to be at-
tuned to the ultimate purpose of the assessment, which needs to
be specified at the problem formulation stage. For allergens in food,
this risk assessment can have two major purposes: (1) the charac-
terisation of a risk associated with a defined (range of) level(s) of
(residual) allergen in a food product and (2) the establishment of
(safe) limit levels for (residual) allergens in food. These are ad-
dressed in more detail in the next sections.
2.3. Development and evolution of practical approaches to the risk
assessment for allergenic foods
Many foods have the potential to provoke allergic reactions in
sensitized individuals (Hefle et al., 1996), but a relatively limited
number has been identified as priority allergenic foods based upon
perceptions of the prevalence, severity and potency of those foods
as allergens (Codex Alimentariu Commission, 1999; EFSA, 2004;
Gendel, 2012). In the EU, the list of priority allergenic foods
comprises peanut, milk, eggs, fish, crustacean shellfish, molluscan
shellfish, tree nuts, soybeans, cereal sources of gluten (wheat,
rye, barley and related grains), lupine, celery, sesame seed and
mustard. Bjorksten et al. proposed a set of consistent scientific
and clinical criteria to identify the most appropriate priority aller-
genic foods based upon defined prevalence, severity and potency
criteria (Bjorksten et al., 2008). While this report focusses on the
priority allergens already identified on the EU list, the approaches
described should be applicable for foods on other lists, where
sufficient data exist.
Multiple approaches have been considered to characterise the
hazard and assess the risk from residues of allergenic foods that
might be present in other foods. The main focus has been on the
risk posed by the potential unintended and variable presence of
those allergenic residues that, not being ingredients, are not sub-
ject to mandatory declaration on product labels. However, similar
approaches could be adapted for allergenic ingredients used at
very low levels. The use of clinical oral food challenge data to de-
velop dose-distribution models for populations with specific food
allergies was first attempted by Bindslev-Jensen et al. (2002). In
a 2007 workshop organized by EuroPrevall, the U.K. Food Stan-
dards Agency, and ILSI-Europe, three main, non-mutually exclusive
risk assessment approaches were identified: (1) safety assessment
using the No Observed Adverse Effect Level (NOAEL) and/or the
Lowest Observed Adverse Effect Level (LOAEL) with application
of uncertainty factors, (2) the Benchmark Dose and Margin of
Exposure (MoE) approach, and (3) the use of probabilistic models
(Madsen et al., 2009). The workshop concluded that the MoE and
probabilistic approaches have merit because they do not rely upon
low-dose extrapolations from dose-distributions derived from clin-
ical challenges with their inherent uncertainties. They also make
use of the whole dataset, in contrast to the safety assessment ap-
proach which relies on a single data point, making it also highly
dependent on the quality of study design. Probabilistic modelling
can be used in conjunction with establishment of Benchmark
Doses. In the U.S., the Threshold Working Group of the Food & Drug
Administration independently considered multiple approaches to
the risk assessment of residues of allergenic foods including a stat-
utorily derived approach, a limit of detection approach, the deter-
ministic safety assessment approach with applied uncertainty
factors, and the quantitative risk assessment (which includes prob-
abilistic modelling) approach (Threshold Working Group, 2008).
This U.S. FDA group also concluded that the quantitative risk
assessment approach provided the strongest and most transparent
scientific approach to establish management or regulatory thresh-
olds for allergenic foods. This group also noted that this approach
was the most data-intensive and that insufficient data were likely
available to use this approach in a robust manner. The European
group also indicated that larger volumes of data on minimum elic-
iting doses were needed to allow effective use of the probabilistic
modelling approach (Madsen et al., 2009).
In the absence of guidance on agreed limits for allergenic resi-
dues, many global food companies have used the limit of detection
as a default criterion, making it a de facto action level. As noted by
U.S. FDA, the limit of detection is not necessarily selected on the ba-
sis of the magnitude of the remaining allergenic hazard (Threshold
Working Group, 2008) and in practice, can be very conservative.
This is especially so when using swabs to verify cleaning as the
methods are highly sensitive as compared to the rate of transfer
from surfaces to products, dilution factors and other considerations.
In Australia, the Food & Grocery Council (trade association)
established The Allergen Bureau of Australia & New Zealand in
an attempt to improve the practice of allergen management and, in
particular curtail the widespread use of advisory or precautionary
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labelling. The Allergen Bureau developed a practical approach to
allergen risk assessment in 2007 known as the VITAL (Voluntary
Incidental Trace Allergen Labelling) programme. An essential part
of the VITAL programme was the establishment of an allergen grid
containing Action Levels to guide the use of precautionary label-
ling. The grid levels were established using a deterministic safety
assessment approach, based LOAELs cited in the U.S. FDA compila-
tion (Threshold Working Group, 2008) and included a 10-fold
uncertainty factor to reflect the limitations of the available clinical
data, including the use of LOAELs rather than NOAELs.
The experiences of the Allergen Bureau offer useful lessons. In
the 2007 version of VITAL, three Action Levels were established
to guide food industry labelling decisions: Green (low risk; no pre-
cautionary labelling); Yellow (possible risk; precautionary ‘‘may be
present: ####’’ labelling recommended); Red (higher risk; defini-
tive ‘‘contains ####’’ labelling recommended). Initially, most of
the green levels were set at <2 ppm of protein from the allergenic
food (exceptions: fish, milk, soy, gluten). While the VITAL pro-
gramme recognised that individual and population thresholds
were actually doses of allergenic protein rather than concentra-
tions, they expressed the Action Levels in terms of ppm of total
protein from the allergenic food since allergen assays give results
as concentrations. However, analytical methods differ in the
expression of their results (e.g. ppm whole food, ppm specific pro-
tein, etc.) as a result of which conversion factors are needed to ap-
ply results. Furthermore, the Action Levels were based upon a 5 g
(approx. one teaspoon) serving size on the assumption that an
allergic person would perceive some reaction before they pro-
ceeded to consume more of the implicated food and would there-
fore be protected. Clearly, many foods are consumed in quantities
well above 5 g and can be consumed in their entirety before a reac-
tion becomes apparent. There is therefore a need to consider con-
sumption patterns and amounts as part of the risk assessment
process. This can be accomplished using quantitative risk assess-
ment as outlined further in this report. The VITAL program was re-
vised in 2011 to incorporate consideration of the availability of
more clinical data and the range of consumption levels for various
foods.
3. Input parameters for the risk assessment: application,
integration, uncertainties and limitations
3.1. Patient-derived data: uncertainties or other considerations in
using controlled food challenge data in risk assessment
Data derived from patients in controlled clinical challenges
form a cornerstone of the risk assessment since they characterise
the hazard associated with a given allergenic food. While this
source of data offers a number of advantages for the risk assess-
ment (e.g. no species to species extrapolation, good evaluation of
individual variability), it also possesses some notable limitations.
As noted above, clinical challenges are controlled in various ways
relating to general health status, medication use, and others that
differ from the wider range of circumstances encountered in a
community setting.
Thus, a legitimate question is the extent to which these results
apply when the individual encounters the allergenic food in the
wider community. Review of the literature reveals a range of fac-
tors associated with the host as well as with the food which could
affect a person’s clinical reactivity on any given occasion and there-
fore potentially their observed minimum eliciting dose (Table 1).
An attempt was made to analyse available clinical literature to
identify factors that could influence MED dose distribution curves
and distinguish those originating at the individual level population
levels, as well as incorporating those associated with the foods, and
assess their possible quantitative impact. However, data are
extremely scarce in this field beyond anecdotal evidence and quan-
titative estimates of the influence of any factor are non-existent for
practical purposes. Many of these factors (i.e., genetic predisposi-
tion and host-environmental interactions) would be expected to
induce minimal variability in estimated threshold doses.
Other sources of variability such as biological cycles, psycholog-
ical factors, stress, and concomitant allergen exposures (e.g. sea-
sonality related to pollen) are likely to already be incorporated
implicitly into the threshold data sets because attempts are not
made to control these factors during clinical challenges. Stochastic-
ity is also likely to be incorporated into existing data sets especially
those data sets involving larger and more unselected groups of
subjects. Food-associated factors, especially food processing and
matrix effects, are likely to be important factors that merit consid-
eration, although their influence will differ by food product. They
are discussed later in this report. To some degree, the argument
can be made that the existing clinical challenge data predomi-
nantly reflects the worst-case scenario by incorporating a mildly
processed form of the food into a rather simple matrix, which
makes it highly bioavailable. Admittedly, this aspect merits addi-
tional clinical investigation and highlights the importance of fully
characterising challenge materials, as well as ensuring that the
allergens are presented in a form that is representative of what is
likely to be encountered in free-living situations.
That analysis leaves activity (especially exercise), infection,
alcohol usage, and medication usage as sources of uncertainty that
differ between the community and clinical settings. The quantita-
tive impact of these factors on threshold doses and therefore on the
probability of reactions has not been well investigated but is
acknowledged to be potentially important. To some degree, they
can ideally be addressed in clinical guidance where food-allergic
patients are given advice to exercise greater care and vigilance
with avoidance diets during times of infection, use of particular
medications, or around periods of intense physical activity.
Variability attributable to the selection of the populations
investigated in challenge studies has already been shown to be
potentially significant (Taylor et al., 2009), but data have not been
published on systematic studies in this area. The practice in many
clinics to exclude from challenges individuals who report prior
Table 1
Factors impacting clinical reactivity and population distribution of minimum eliciting
doses.
Host-associated factors
Genetic predisposition (incl. gender, race)
Circadian, menstrual and other biological cycles (incl. age)
psychological factors
Environmental factors (possibly acting as a secondary danger signal)
Activity (incl. exercise)





Comorbid disease (e.g. asthma, cardiovascular disease, etc.)
Day-to-day intra-individual variability
Population-associated factors
Demographics (age distribution, etc.)
Selection (e.g. clinic population)
Geography and culinary practices
Type of study (e.g. immunotherapy trial, threshold)
Food-associated factors
Food variability (e.g. cultivars, seasonality, etc.)
Food processing (e.g. boiling, frying, baking, etc.)
Matrix effects (e.g. high fat, bioactive compounds)
Stochasticity (inherent ‘randomness’, frequently encountered in biological
systems)
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severe (anaphylactic) reactions may reduce the representation of
individuals with greater sensitivity, and therefore lower MEDs,
although this remains unproven and the quantitative impact has
not been estimated (e.g. by considering the proportion of individ-
uals excluded). However, the more profound impact will result
from the exclusion of less sensitive individuals who are able to
manage their allergies without recourse to clinical help. A conse-
quence of their ability to manage is that they will often not be re-
cruited into studies since they will not be known to the relevant
health services. Furthermore, they will probably not be motivated
to participate in a procedure which requires a significant invest-
ment of their time for no clear benefit. Thus, the overall result of
population selection biases will tend to make estimates of popula-
tion eliciting doses rather conservative.
3.2. Dose-distribution of minimum eliciting doses: modelling and
application to risk assessment
Initial approaches to establish safe limits for allergenic residues
focussed on a deterministic approach based on identifying a NOAEL
for the allergic population. Empirically, clinical investigators have
known for many years that, once sensitized, some food-allergic
individuals could react adversely to ingestion of small quantities
of an allergenic food (Gern et al., 1991; Malmheden-Yman, 2004).
However, no one knew exactly how small the amounts needed to
be. Blinded oral food challenges were (and remain) the only
unequivocal means for the diagnosis of food allergies but the pro-
cedure itself has evolved and adapted to new requirements. Early
investigations started at doses of 500 mg of food (Bindslev-Jensen
et al., 2004; Bock et al., 1988) and resulted in a substantial propor-
tion (20% or more) of patients reacting at the first dose, and there-
fore could not establish a NOAEL (Sicherer et al., 2000). As
challenge procedures were refined and improved, particularly with
the inclusion of very low starting doses, it rapidly became apparent
firstly that the ultimate population NOAEL would be elusive, but
more importantly that it might prove so low that it would be
unsuitable for risk management decisions and finally that it would
make very poor use of the growing body of data. These observa-
tions, together with the growing volume of data on low dose food
challenges, thus spurred consideration of alternatives to the classi-
cal chemical safety assessment.
The more widespread use of low dose oral challenges in clinical
practice has confirmed that each food-allergic individual has a
threshold dose below which they will not experience an adverse
reaction upon ingestion of the allergenic food (Hourihane et al.,
1997b; Taylor et al., 2002). Thus, double-blind, placebo-controlled
food challenge (DBPCFC) trials in clinical settings provide human
data on food-allergic individuals that can be used for risk assess-
ment purposes.
Before evaluating the clinical data for possible use for risk
assessment purposes, several definitions must be established start-
ing with a definition for the term, threshold. Clinically, the thresh-
old dose is operationally defined as the lowest dose capable of
eliciting an allergic reaction and can also be termed the LOAEL or
the minimum eliciting dose (MED) (Crevel et al., 2007). However,
for risk assessment purposes and in parallel with general toxico-
logical practice, the NOAEL, the highest amount of the allergenic
food which will not cause a reaction in a particular individual aller-
gic to that food, is also important. In the existing clinical literature
from low-dose oral challenge trials, individual LOAELs are reported
but NOAELs are often not, but can be discerned if the dosing
scheme is provided. The precision of both the LOAEL and the
NOAEL are dependent on study design, which therefore also con-
tributes to uncertainty.
To determine an individual NOAEL or LOAEL, agreement must
be reached on what constitutes an allergic reaction. In the existing
clinical literature from low-dose challenge trials, both subjective
responses and objective reactions have been reported. Objective
reactions are responses apparent to an external observer, such as
urticaria, erythema, and vomiting. Subjective responses, such as
palatal itching, and nausea, are, by definition, not apparent to
external observers, such as clinical staff, and their recording is
dependent upon the verbal comments of the patients, often in re-
sponse to questioning from staff. Because of their nature, objective
reactions can be considered generally a more reliable indication of
a specific response to a food. In clinical settings, objective symp-
toms can be confirmed to occur and their reproducibility readily
assessed. Furthermore, use of an objective marker reduces poten-
tial uncertainty in interpretation of symptoms when different
populations are analysed together (e.g. infants and adults or older
children). In low-dose challenge trials, severe reactions are not
typically encountered. In contrast, subjective symptoms such as
non-cooperation (in children particularly) or itch are easily elicited
but difficult to quantify on a consistent basis between clinical
investigators and can be difficult to attribute unequivocally to a
specific response to the food. While subjective responses provide
valuable information and should be recorded, consensus was
reached that the NOAEL and LOAEL should be established on the
basis of the doses provoking the first objective reactions in DBPCFC
trials, with abdominal pain in infants and young children as the
main exception.
Current dose distribution models are asymptotic and therefore
do not define a dose at which no individual is predicted to react.
However, operationally, the population threshold can be defined
as the largest amount of the allergenic food which will not cause
a reaction when tested experimentally in a defined population of
allergic individuals e.g. all tested peanut-allergic individuals (the
population NOAEL). This definition relies upon the presumption
that a representative group can be identified within the global pop-
ulation of individuals allergic to a specific food and tested clinically
with oral challenges. The degree to which the tested group repre-
sents the overall population with a specific food allergy is a source
of potential uncertainty.
While population eliciting doses are likely to be conservative
estimates for reasons discussed previously, concern has been
voiced that some of the most highly sensitive individuals (as de-
fined by dose) might have been excluded from challenge studies.
However this concern equates sensitivity with a history of severe
reactions, a link which still remains to be proven. In a retrospective
study of peanut thresholds, Taylor et al. (2010) observed no differ-
ence between those of peanut-allergic patients who reported
histories of severe reactions and those of patients whose previous
reactions had been less severe. Another recent challenge study
found no consistent relationship between the dose at which
reactions occurred and the severity of the reaction (Rolinck-
Werninghaus et al., 2012). Considerable variation exists among
individuals with a specific food allergy with respect to their indi-
vidual NOAELs and LOAELs (Crevel et al., 2007). In an examination
of individual thresholds among 450 peanut-allergic individuals,
the range of individual LOAELs spanned five orders of magnitude
from 0.1 mg up to 2.5 g of peanut protein or 0.4 mg to 10 g of
whole peanut (Taylor et al., 2010). Given that such a wide range
of individual LOAELs exist, the selection of patients for oral chal-
lenge trials used to establish population thresholds becomes quite
important, as is an accurate description of the allergological status
of the participants. Thus the data should be examined carefully to
ascertain whether the selected patients are representative or
skewed in favour of selection of patients likely to react to lower
doses. Ideally, it should be possible to map the characteristics of
the challenged individuals onto the overall population allergic to
the food under study and thereby identify biases that might need
to be corrected, or at least acknowledged in the risk assessment
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conclusions. However, comparative studies have not been per-
formed between patients from different geographical areas, pa-
tients of different ages, the same patients in different seasons
(e.g. pollen season), or patients with differing symptoms. Instead,
existing evaluations have used data from patients from all groups.
In practice, the expertise required to perform challenge studies
means that they are generally performed in tertiary care reference
clinics, where the overall patient populations are more likely to
have multiple allergies and a history of at least one severe reaction.
However the selection of individuals for challenge studies may not
necessarily mirror the clinic population as a whole.
When examining clinical information for the purpose of estab-
lishing population thresholds, variations in clinical challenge pro-
tocols must be considered. A consensus protocol for low-dose
clinical challenges has been developed (Taylor et al., 2004) and
close variants applied to large-scale studies (Crevel et al., 2008).
Widespread consensus has been achieved on various protocol
elements such as withholding of certain medications before and
during challenges, time intervals between doses, use of placebo-
controlled crossover designs, use of objective symptoms (or
abdominal pain in infants and young children) as the criterion
for stopping challenges, and fasting period before challenges. How-
ever, comparison of data from clinics which used different proto-
cols must take into account various other factors must be
considered such as the nature of the challenge materials, the ma-
trix for blinding of challenges, and dosage schemes (Crevel et al.,
2008).
Challenge materials are a critical variable in challenge studies
and should be fully characterised, as in any safety study, both with
regard to the active material (the food to be blinded) and the actual
dose present in the matrix. The outcome of challenges can be
affected by the form of the allergenic food, the vehicle, or the type
of processing used in the preparation, which may, for instance, al-
ter the proportions of different allergenic proteins (Ballmer-Weber
et al., 2007). The form of the allergenic food (e.g. peanut flour vs.
ground roasted peanuts vs. peanut butter or soya flour v soya milk)
and the extent to which it is processed varies between challenge
protocols but may not be important in the case of foods such as
peanuts where allergens are thought to be heat-stable. With milk
and egg however, challenges should ideally use less processed
forms of food such as pasteurized, spray-dried or even raw, where
possible. Recent clinical studies have documented that many milk-
and egg-allergic patients become tolerant of baked milk or egg
before they develop a tolerance for these foods in forms that are
subjected to lesser degrees of heat processing, and this is reflected
in increased individual thresholds (Lemon-Mule et al., 2008;
Nowak-Wegrzyn et al., 2008). The use of raw or mildly processed
foods thus appears to represent a worst-case situation relative to
individual threshold doses but the materials used need to reflect
those used in commercial food production since they are the
principal subject of the risk assessment. The outcome of challenges
may also be dependent upon the composition of the vehicle used
for challenges such as the level of fat e.g. chocolate vs. other
vehicles (Grimshaw et al., 2003; Cochrane et al., 2012).
The dosage schemes used in clinical challenge protocols also
vary. However, a statistical approach called interval-censoring sur-
vival analysis has been developed that adjusts to different dosing
schemes and is likely to remove this factor from consideration,
although results can still be influenced if a large proportion of
the data are not interval-censored (e.g. first dose reactors) (Taylor
et al., 2009).
Beyond clinical protocol variables, the results of DBPCFCs must
be evaluated on the basis of several other factors. For example,
challenge doses are typically administered at intervals of
20–30 min that probably do not allow for complete assimilation
of one challenge dose before the next dose is administered. It is
therefore not possible to know with certainty whether a reaction
occurred in response to the last dose administered, a delayed
response to a prior dose or to the cumulative dose ingested.
Challenge results can thus be analysed in terms of both discrete
and cumulative doses. The nature of the population selected for
challenge is another variable, which has already been discussed.
However, separate analysis of different (sub)populations (e.g. chil-
dren vs. adults) may provide valuable insights, although only
where a sufficient volume of data make it statistically valid.
Geographical, ethnic or other differences might also occur between
sub-populations with a particular food allergy but clinical data to
establish a basis for such differences are still very limited outside
the well-known influence of pollen sensitisation on certain food
allergies. Potential resolution of certain food allergies such as milk
and egg in infants and children (Sampson, 1996) must also be
taken into account in evaluating data from such populations.
3.3. Statistical dose-distribution modelling and establishment of
reference doses
While the determination of individual threshold doses for food-
allergic patients is not currently a common clinical practice, data
from low-dose DBPCFC trials have become increasingly available
in recent years. In the published clinical literature, individual
threshold data can be found from three different types of studies
– diagnostic series, threshold studies and immunotherapy trials
(Taylor et al., 2009; Skripak et al., 2008; Clark et al., 2009). Allergy
clinics are also likely to have potentially useful but unpublished
individual threshold data. From the available clinical information,
statistical dose-distribution modelling of individual NOAELs and
LOAELs can be used to derive information useful in the establish-
ment of a population threshold.
Published clinical data relevant to thresholds are typically not
presented in a consistent format. Some of the key differences be-
tween studies are described elsewhere in this report. A first step
in analysing these data is to normalize them to allow inclusion of
data from multiple centres and studies. For the purposes of this re-
port, threshold data are normalized to total protein content from
the allergenic source. The use of total protein from the allergenic
source is an appropriate unit of measure because food allergens
are proteins, and represents a pragmatic solution, since data, such
as detailed characterisation of the foods used in challenges, are not
generally available to perform a more sophisticated normalization
Since different forms (e.g. liquid, solid, etc.) of an allergenic food
can be used in various studies, normalizing on the basis of total
protein from the source corrects for any differences that might ex-
ist on a food weight basis. Furthermore, analytical methods for
allergenic foods are often based on the total protein content allow-
ing intake assessment to be matched to reactive doses.
The statistical models using data from the clinical challenge
studies allow the derivation of an eliciting dose (ED), where EDp
refers to the dose of total protein from the allergenic food that is
predicted to produce a response in p% of the allergic population
(Crevel et al., 2007). This approach enables the identification of a
dose of an allergenic food protein (EDp) at or below which a de-
fined proportion of the allergic population would be likely to react
to but, importantly, does not identify a dose below which no aller-
gic individual would react. The reference doses described in this re-
port (Table 2) were derived from clinical data obtained from
DBPCFC trials except in the case of infants and young children
where blinding is considered not necessary. The endpoints of indi-
vidual challenges were the provocation of objective symptoms
with the exception of abdominal pain in infants and young chil-
dren. The data were modelled on the basis of both discrete and
cumulative doses.
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Where possible, individual data were gleaned from published
clinical research. Publications were selected using criteria outlined
previously in particular focusing on DBPCFC trials involving use of
low doses. Additional unpublished data were obtained from sev-
eral clinics in the Netherlands and Berlin, Germany (gathered by
TNO) and from partially completed threshold research studies
sponsored by the Food Allergy Research & Resource Program of
the University of Nebraska (USA). The NOAEL and LOAEL for objec-
tive responses were recorded for each subject in units of mg of to-
tal protein from the allergenic food. For each subject, the true
threshold dose lies, by definition, between the NOAEL and LOAEL
doses. Individual threshold data were analysed using interval-cen-
soring survival analysis (Taylor et al., 2009). The data were fitted to
the parametric models using the SAS LIFEREG procedure (SAS v9.1)
as described by Taylor et al. (2009). Several parametric models (log
normal, log logistic, Weibull) were used to fit the individual thresh-
old data for each allergenic food. The totality of evidence from all
three models was considered in deriving the appropriate EDp, as
well as the overall goodness of those fits, rather than attempting
to select the single apparent best fit. This approach was deemed
more robust since there is currently no biological rationale to pre-
fer one parametric model over another. The outcome of the dose-
distribution modelling was the derivation of a reference dose in
units of mg of total protein from the allergenic food.
3.3.1. Basis for the reference doses
Reference doses represent a judgement about accepted risk.
Where the data from clinical challenges were of sufficient quality
and quantity, the ED01 was selected as the reference dose. In prac-
tice, the ED01 is the most stringent value that can be generated
with confidence even with the datasets for which the data are most
abundant. In particular it avoids low dose extrapolation, where the
result is heavily dependent on the statistical model used rather
than the input data (Crevel et al., 2007). The significance of the
ED01 must also be appreciated. Dose distribution models describe
the frequency of challenge responses associated with objective
individual thresholds and presumably milder responses than incre-
mental doses associated with the more severe reactions that are
consistent with anaphylaxis, which would likely be represented
by a parallel dose distribution shifted to the right. Thus, a reference
dose based on the ED01 would be expected to protect at least 99%
of people allergic to the particular food from any objective reaction
and minimize the probability of any serious reaction occurring in
the remaining 1%. Nevertheless, acknowledging that these highly
sensitive individuals in the population may be avoiding
commercially processed foods due to prior experiences of adverse
reactions to these products in the community, the possibility of a
reaction of greater severity than a mild objective reaction occur-
ring in a very small fraction of this remaining 1% of the allergic
population cannot be excluded on the basis of current knowledge.
In situations where the data were insufficient to allow estima-
tion of the ED01, the lower 95% confidence interval of the ED05
which would likely protect 97–99% of the affected population
was selected as the reference dose. The lower 95% confidence inter-
val reflects the uncertainty around the ED05 estimate and is thus
preferable to an arbitrary uncertainty factor directly applied to
the ED05. Because the ED01 or the 95% lower confidence intervals
of the ED05 based upon human clinical data were used, additional
uncertainty factors were not incorporated into the establishment
of the reference doses (see Section 3.3).
The dose distributions for both discrete and cumulative doses
were modelled separately using each of the three parametric mod-
els. While use of the discrete dose is the most conservative choice
for risk assessment purposes, little difference was observed in ED
values on this basis so the models based on both discrete and
cumulative doses were considered in every case in the derivation
of the reference dose, as were each of the different statistical mod-
els. Insufficient data existed to allow separate threshold dose dis-
tributions to be built for infants and children (up to the age of
18 years) versus adults except in the case of peanut. In some cases
such as milk and egg, most of the available data pertained to in-
fants and children, while in other cases (hazelnuts), the majority
of the data were available for adults. Also, many studies did not re-
port age data in sufficient detail (i.e. at the individual patient level).
Thus, the data for both children and adults were combined for
most allergenic foods for purely pragmatic reasons and to increase
the robustness of the statistical analyses.
In the future, it would be desirable to have individual threshold
data stratified by age into narrower age ranges such as exist for
nutritional databases e.g. 0–3 years, 4–6 years, etc. For some foods
such as milk and egg where the allergy is often outgrown, young
children are likely to represent the most sensitive segment of the
population. The effect of age, if any, is less certain for foods such
as peanut where allergy is more persistent. As more age-specific
data become available in the future, any differences in the distribu-
tions for children and adults should be considered.
For each allergenic food, Table 2 provides the total number of
subjects with a clinically determined individual threshold, the
number of left-censored and right-censored subjects, the number
of subjects found in publications and from unpublished clinical
Table 2
Number of threshold data points gleaned from publications and unpublished clinical records and reference doses derived by the VITAL scientific expert panel (from Taylor et al.,
2014).
Allergen Total with Objective Symptoms Right Censoreda Left Censoredb Population Basis of Reference Dose Reference Dose (mg total protein)
Peanut 750 132 30 Children and Adults ED01 0.2 mg
Milk 351 19 59 Children and Adults ED01 0.1 mg
Egg 206 33 24 Children and Adults ED01 0.03 mg
Hazelnut 202 67 4 Children and Adults ED01 0.1 mg
Soybean 80 28 6 Children and Adults LCI ED05 1.0 mg
Wheat 40 1 5 Children and Adults LCI ED05 1.0 mg
Cashew 31 16 1 Children Hazelnut (ED01) 0.1 mg
Mustard 33 10 2 Children and Adults LCI ED05 0.05 mg
Lupin 24 7 2 Children and Adults LCI ED05 4.0 mg
Sesame 21 1 2 Children and Adults LCI ED05 0.2 mg
Shrimp 48 26 0 Adults LCI ED05 10 mg
Celery 39 4 15 Children and Adults NR
Fish 19 2 6 Children and Adults LCI ED05 0.1 mg (provisional)
NR: No recommendation.
a Number of right-censored subjects (NOAEL = highest challenge dose; LOAEL set to infinity).
b Number of left-censored subjects (NOAEL set at zero; LOAEL = lowest challenge dose).
R.W.R. Crevel et al. / Food and Chemical Toxicology 67 (2014) 262–276 269
records, and the clinical population (children and/or adults) where
age was indicated in the publications and unpublished records.
Sufficient data, i.e., enough data points to ensure that the ED value
was not generated by low-dose extrapolation beyond the lowest
data point (Crevel et al., 2007), were found for peanut, milk, egg,
and hazelnut to allow use of the ED01 as the reference dose. Smal-
ler amounts of individual threshold data were found for soybean,
wheat, cashew, mustard, lupin, sesame seed, shrimp, celery and
fish. In the case of fish, different species had also been used. For
the foods with smaller available data sets, the risk assessment
would be enhanced by additional data.
These data have previously been evaluated by a Scientific Ex-
pert Panel on behalf of the Allergen Bureau of Australia and New
Zealand during the recent revision of the VITAL programme. The
findings of that group have now been published and include more
extensive assessment of the data for each of the allergenic foods
(Allen et al., 2013; Taylor et al., 2014). For the most part, existing
data were sufficient to allow development of reference doses at
the ED01 or the 95% lower confidence interval of the ED05. How-
ever, several data gaps and uncertainties remain.
While a reference dose of 1.0 mg of wheat protein was estab-
lished with respect to IgE-mediated wheat allergy, the question
arises whether this reference dose would also be protective of coe-
liac patients. The Codex guideline for gluten-free products is
<20 ppm gluten which was established based upon a no-effect le-
vel of 10 mg of gluten per day from a 90-day intervention study
(Catassi et al., 2007). On this basis, wheat-allergic consumers could
safely consume 50 g of a gluten-free product having 20 ppm glu-
ten. However it is currently not clear whether certain gluten-free
products may still contain small amounts of non-gluten wheat pro-
teins and the ensuing residual risk, if any, to some people with
wheat allergy.
Data on soybean thresholds were more problematic because
some soy-allergic individuals have recently been identified who re-
act to certain types of soy milk but can safely consume other forms
of soy (Mittag et al., 2004). Since these individuals are not appar-
ently allergic to all forms of soy, the data from such patients rela-
tive to thresholds were not included in the analysis. Instead,
reliance was placed on individual threshold data from patients
reactive to soy flour who apparently react to all forms of intact
(non-hydrolyzed) soy protein. However, the possibility of several
forms of soy allergy with perhaps differing threshold doses merits
further investigation. With crustacean shellfish, sufficient data ex-
ist to establish a reference dose for shrimp. However, no data exist
on individual thresholds for other species of crustacean shellfish
such as crab and lobster. Similarly no relevant data were identified
for any molluscan shellfish. Thus, uncertainties remain regarding
whether the reference dose for shrimp can be also applied to crab
and lobster.
Several data gaps were also identified. Insufficient data exist on
celery and fish to allow establishment of a reference dose. With
fish, the situation is possibly complicated by the existence of
numerous fish species. Uncertainty remains regarding whether a
reference dose for one species of fish would extend to all fish spe-
cies. With the tree nuts, sufficient data existed on individual
thresholds for hazelnut to allow establishment of a reference dose
at the ED01 level. Threshold data were available from 31 cashew-
allergic individuals, however, the data were found only on children
from one Dutch clinic so some uncertainty exists regarding
whether this threshold distribution would be representative of
adults and cashew-allergic patients from other geographic loca-
tions. A complete absence of data was found for most of the other
tree nuts on the EU list (walnut, almond, pecan, pistachio, Brazil
nut, macadamia nut). Thus, it would be premature to establish a
reference dose for any tree nuts, other than for hazelnut at this
time. The Allergen Bureau of Australia and New Zealand decided
to use the reference dose for hazelnut (0.1 mg protein) for all other
nuts, while recognising the shortcomings of that strategy.
4. Intake assessment (consumption and contamination, quality
and quantity of data, differences in behaviour, quality of
analytical methods)
4.1. Exposure assessment
As discussed previously, risk is a function of hazard and expo-
sure, which is therefore a critical component of risk assessment.
With allergenic foods mandated to be labelled whenever used as
ingredients, the relevant exposure in food allergy risk assessment
is the exposure to unintended presence of allergens i.e. contamina-
tion. However, the approach described could also be adapted as a
basis for labelling decisions on clinically trivial amounts of aller-
genic ingredients in products. Exposure assessment has two com-
ponents: the level of contamination and the intake (amount and
frequency) of the culprit food or foods. Both the level and fre-
quency of contamination in a product along with the estimated
product consumption (and frequency) can be used in food allergy
risk assessment to generate an allergen intake distribution. Quan-
titative risk assessment such as probabilistic modelling (described
in detail in a later section) can be used to estimate the probability
of an allergic reaction occurring based on the concentration of the
allergen in the product, the amount of product consumed, and the
probability that an allergic person with a threshold lower than the
allergen content would consume it. Accurate exposure assessment
thus plays an important role in the overall risk assessment and a
number of variables must be carefully considered as discussed
below.
4.2. Food intake
Symptoms of IgE-mediated reactions to food in general appear
within minutes up to a few hours after exposure. It is assumed that
food allergens, if they do not cause disease, are eliminated between
meals, with the prerequisite that meals are at least 2–3 h apart. The
exposure scenario for risk assessment is therefore based on intake
of the specific food during one meal or eating occasion.
Many countries collect dietary data in food surveys in a format
which allows calculation of the daily intake of a particular food or
food group and sometimes also intake of that food per meal in dif-
ferent age groups as well as the frequency of that intake. For prac-
tical reasons dietary surveys assemble the same category of food in
food groups. From country to country the grouping and level of de-
tail may vary. Bread may be a food group in one country. In another
country bread may be divided into wheat bread, wheat bread with
kernels, wheat bread with seeds and nuts, rye bread, rye bread
with kernels or rye bread with seeds or nuts. The underlying pur-
pose behind food intake surveys is to estimate nutrient intake and
understand dietary habits e.g. intake of fruits, vegetables, red meat
or soft drinks. They are also used to estimate chronic intake of var-
ious environmental contaminants (e.g. heavy metals, carcinogens,
etc.). The structure of dietary data reflects these purposes and is of-
ten not optimal for food allergen risk assessment. In Europe there
is only food intake data suited for food allergen risk assessment at
a national level. Although many foods are produced for a pan-Euro-
pean market, risk assessment therefore currently needs to be done
country by country. The range and type of food products sampled
will therefore also differ and will depend on the specific risk
assessment question, as discussed later.
National food surveys are performed on a representative sample
of the population using a variety of methods, including recall and
food diaries. In the latest survey from Denmark, covering the
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period 2003–2008, self-reported food allergy was mentioned by
310/2670 (11.6%) of those surveyed. Clearly those with a food al-
lergy should avoid foods containing as an ingredient the allergen
to which they react, and this will be reflected in the survey in most
cases. However, such surveys do not provide information about the
consumption by allergic people of products that could contain,
through cross-contact, the allergen to which they react. Although
for purposes of conducting any risk assessment, it must be as-
sumed that if a food-allergic person eats a certain food, the amount
and frequency of consumption is similar to that of the general
population, this is almost certain to result in under- and over-
estimates of the risk in many circumstances. Under-estimates
would arise when food-allergic individuals substitute and consume
one food more regularly than another. For instance, individuals
with coeliac disease or wheat allergy following a gluten-free diet
might consume more rice than the average person. If that rice were
contaminated with wheat, any such individual with coeliac disease
who also had a wheat allergy could be at higher risk of wheat-
associated reactions from rice than the general population. Over-
estimates could arise if individuals with a specific food allergy
actively avoided all foods perceived as ‘‘risky’’;, for example, milk
allergic subjects avoiding all chocolate. Thus, the risk of reaction
from consumption of undeclared milk in chocolate would be much
less than estimated for the general population. A general assump-
tion remains that the amount of food consumed by food-allergic
individuals and its distribution will be similar to that consumed
by the general population. While this may be a reasonable assump-
tion for most food scenarios, formal proof is currently lacking.
In chemical risk assessment the mean intake per day of a food
group in the whole population is often used. This figure is not very
useful in food allergy risk assessment as it does not say anything
about the amount of food consumed on one meal occasion. As an
example the mean consumption of wheat bread per meal in the
Danish adult population includes all those who do not eat bread
at a meal and does not therefore correspond to the actual amount
eaten and therefore the risk incurred if it is contaminated by an
allergen. A more relevant figure is the mean consumption based
on the persons eating bread (eaters only). The consumption may
also be expressed as a percentile (e.g. the 95th percentile) intake
in eaters only. In a worst case scenario the maximum intake of
the food may be used. Using data from the Danish National Food
Survey the mean intake per meal of wheat bread is 75 g. The
95th percentile is 154 g and the maximum per meal is 355 g. It is
apparent that the measure of intake varies considerably depending
on the data chosen. All the data presented are valid descriptions of
wheat bread consumption, but the outcome of the risk assessment
will be heavily influenced by which intake data are chosen.
Probabilistic risk assessment is not restricted to using one data
point for intake (e.g. mean intake of eaters only) but can include
the whole distribution of intakes across the population. If we use
the bread example again it will be possible to include individual con-
sumption data that include portion sizes and frequency of intake.
A food producer may want to know if contamination of a prod-
uct with a particular amount of an allergen could pose a risk to
consumers allergic to the specific contamination. Public health
authorities may also want to know if a specified level of contami-
nation would still remain acceptable if it occurred in more than
one product or category of products. A scenario with contamina-
tion of more than one food with the same allergen is described
in Section 5.2 below.
There has rightly been much emphasis on getting and using the
best possible food challenge data as a basis on which to determine
reference doses. The choice of food intake data also influences the
outcome of the risk assessment and the quality of food intake data
is therefore also an important consideration regarding the impact
of allergens on public health.
4.3. Level of Contamination
The concentration of allergenic food residue (or protein from
the allergenic source) can be determined either through calcula-
tion or by quantitative analysis of the ingredient or finished food
product in question. Calculation of the concentration of allergenic
residue can be made in instances where unintended allergen
may have been included in a formulation at a consistent level
(e.g. a flavour supplier changed the formulation to include a milk
ingredient but failed to notify the manufacturer of the finished
food). The most common approach to determining the concentra-
tion of allergenic residue is through quantitative analysis of the
ingredient or finished product. Since specific proteins from the
allergenic source are targeted by the immune system during IgE-
mediated food allergy, the analytical method used to assess the po-
tential concentration of allergenic residue would ideally detect
proteins from the allergenic source either as total protein, a certain
protein fraction (e.g. casein), or a specific allergen (e.g. Ara h 1 from
peanut). However, in risk assessment terms, the critical point is to
be able to relate an analytical value to the human threshold data
from clinical challenges as discussed below.
Immunochemical methods such as Enzyme-Linked Immunosor-
bent Assays (ELISA) have become the standard method used by the
food industry for both qualitative and quantitative detection of
allergen residues in food products or on equipment contact sur-
faces (Wang et al., 2010; Jackson et al., 2008). ELISAs are the fa-
voured analytical methodology as they detect protein(s) from the
allergenic source of interest, are sufficiently sensitive with detec-
tion limits in the low milligram per kilogram (ppm) range, and pro-
vide rapid assessment that can be run in the food processing
facility or in a food industry laboratory (Jackson et al., 2008). Tests
based on the polymerase chain reaction (PCR) are available for
detection of DNA from a number of allergenic sources where ELISA
methods may not be available. PCR tests do not however detect
proteins from the allergenic source so their utility in food allergy
risk assessment is limited (van Hengel, 2007). Advances in the
use of mass spectrometry methods for the qualitative and quanti-
tative detection of allergenic food proteins have been made over
the past few years (Johnson et al., 2011). An advantage of mass
spectrometry over PCR methods is that mass spectrometry meth-
ods can detect the allergenic proteins of interest and thus can pro-
vide a direct evaluation of the level of allergenic residue of concern
for risk assessment purposes. The limits of detection and quantifi-
cation of mass spectrometry methods are approaching the sensitiv-
ity of ELISA methods in several food matrices that have been
examined and may provide a reliable confirmatory method in the
foreseeable future. Other analytical methods such as the Adenosine
Tri-Phosphate (ATP) test and total protein tests are utilized by food
industry for routine monitoring of cleaning and sanitation but are
not specific for the detection of proteins from the allergenic source
of interest. While these methods are useful tools for monitoring the
cleaning process, they do not provide the quantitative detection of
specific proteins from the allergenic source of interest that is
needed to conduct a thorough risk assessment.
ELISA methods do have their inherent differences from one
commercial method to the next and these need to be fully under-
stood and carefully considered and controlled for to ensure that the
results are meaningful and can be applied to the risk assessment
process. Immunochemical methods such as ELISAs utilize animal
IgG antibodies that are directed against either specific allergenic
proteins or, in most cases, several proteins from the allergenic
source of interest (but not limited to proteins that cause IgE-med-
iated food allergy in humans). Interpretation of the results ob-
tained from ELISA testing becomes a very important part of the
overall allergen risk assessment process. As discussed previously,
use of realistic consumption estimates for the particular product
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can then be used along with the analytical data from ELISA testing
to calculate the dose per eating occasion and determine if the prod-
uct contains amounts of allergenic residue at or below the refer-
ence doses for the specific allergen of interest. Converting the
analytical data from ELISA methods is not always a straightforward
calculation as some commercial ELISA kits report results in ppm of
whole food, some in ppm protein, and others on ppm of a specific
whole allergenic food. It is very important to determine the units in
which the ELISA results are reported so that the proper conversions
can be made. Detection of milk residue serves as a good example as
there are commercial ELISA kits that detect ‘total milk’ (protein
from both the casein and whey protein fractions of milk), caseins,
and beta-lactoglobulin (BLG; from the whey fraction of milk). Some
of these kits will report the results in ppm (mg/kg) non-fat dry milk
(NFDM), ppm casein or ppm BLG.
Appropriate conversion factors need to be incorporated to
determine the concentration in units of milk protein to correctly
compare the exposure dose (in mg milk protein) to the reference
dose for milk (0.1 mg milk protein) which is based on the popula-
tion threshold distribution of milk-allergic individuals. NFDM con-
tains approximately 35% milk protein so if the ELISA results
indicate that 10 ppm NFDM are present in the food product, a level
of 3.5 ppm milk protein would be present. Caseins accounts for
approximately 80% of milk protein so 10 ppm casein would corre-
spond to 12.5 ppm milk protein. Milk contains approximately 10%
BLG so a concentration of 10 ppm BLG corresponds to 100 ppm
milk protein. Misinterpretation of the analytical results could
clearly have significant effects on the overall risk assessment.
Proteins are also known to vary in terms of thermal and prote-
olytic stability, which can affect extraction and detection of the
allergenic protein residue of interest. However inability or reduced
ability to detect an allergen in an assay as a result of such changes
does not necessarily translate to absence of, or reduced allergen-
icity. For instance, detection of BLG after thermal processing treat-
ments such as baking has been shown to decrease likely due to the
protein becoming insoluble (Downs and Taylor, 2010), but it re-
mains to be shown through controlled challenges whether the
allergenicity of the BLG has been reduced. It is always critical to
validate that the ELISA will detect the allergenic residue of interest
reliably, and where appropriate quantitatively, by analysing a posi-
tive control sample (a sample that is known to contain a given
amount of the allergenic source of interest). As demonstrated,
use of analytical methodology must be carefully considered when
results are to be applied to the exposure assessment and the over-
all risk assessment process to ensure that a realistic estimation of
risk can be made.
Probabilistic risk assessment as discussed in detail in the fol-
lowing section can incorporate the distribution, rather than a point
estimate of the unintended allergenic residue into the risk assess-
ment model. Analytical assessment of a number of samples taken
from a batch or multiple batches of production can be used to
establish a distribution of the concentration of allergenic residue
that may be expected over time during a production cycle. Select-
ing a sufficient number of samples to obtain a representative distri-
bution of the expected concentration of the allergenic residue is
somewhat straightforward when the allergenic residue of concern
is homogeneously distributed in the product of interest. Sampling
becomes more challenging when the source of contamination is
due to particulates which can be randomly distributed throughout
the product in question. In this instance, the likelihood and size
distribution of the particulate contamination, along with the dose
distribution (based on the expected size distribution of the parti-
cles) can be included as input variables in the risk assessment
model. Development of approaches to manage particulate contam-
ination with food allergens is in its very early stages and has not
been investigated experimentally. Validating or verifying the
outputs of such models will likely prove quite challenging and will
depend on the ability to develop robust sampling plans. Such a
situation is analogous to that encountered in verifying microbio-
logical standards and a first approximation would therefore be to
design a sampling plan based on the approaches developed to
demonstrate compliance with microbiological specifications
(Codex Alimentarius Commission, 1999a; WHO-FAO, 2008).
5. Safety and risk assessment
5.1. Elaboration of action levels: translating hazard characterisation to
risk assessment
The previous two subsections describe hazard characterisation
and exposure assessment respectively. As previously discussed,
several approaches can be used to combine these two elements
of risk assessment, depending on the risk management question
posed and the amount and quality of data available. This section
describes how advanced techniques which take into account the
totality of the available data can be used to assess the risk from
the unintended presence of food allergens. It considers in particu-
lar how these data may be combined with information on food in-
take and unintended allergen concentration to derive action levels,
which are quantitative benchmarks for allergen management. An
action level in this context is the concentration in a product of pro-
tein from an unintended allergenic constituent which would deli-
ver a dose of allergen equivalent to the accepted reference dose.
Operationally, action levels can serve to define the concentrations
of allergen below which a precautionary warning would be
deemed unnecessary because the risk posed by the presence of
unintended allergen was below the accepted level of risk as de-
fined by the relevant reference dose. In contrast, concentrations
in excess of the action level would trigger additional risk reduction
measures or, if not feasible, a precautionary warning.
Action levels can be derived from reference doses and food in-
take and contamination data in several ways. Two approaches,
deterministic and probabilistic are illustrated in Fig. 1 below.
The deterministic approach, illustrated by method 1 in the fig-
ure describes a simple arithmetical method and can be used when
no or limited data are available on the consumption of the food of
interest or its distribution. It is also most practical for elaboration
of action levels by industry.
Action levels can most easily be calculated from an ED-value
chosen as a reference dose and an assumed intake (portion size)
by the following formula:
½EDp ðin mgÞ=Intake ðin kgÞ ¼ action level ðin mg=kg or ppmÞ
EDp: dose calculated to elicit an allergic reaction in p% of allergic
individuals.
Clearly when elaborating action levels through combination of a
chosen food consumption figure and an ED-value, the choice of the
appropriate consumption figure is critical. This can be illustrated
by the following example.
A reference dose of 0.2 mg protein was elaborated for peanut
based on a proposed maximum accepted risk of 1% (see Table 2
and Section 5.2). In the Netherlands, one slice of bread is consid-
ered the portion size for sliced brown wheat bread, but the mean
consumption per meal occasion is 140 g, while the p95 intake for
male users of brown wheat bread is 210 g. The action level based
on a 35 g portion size is 5.7 ppm, whereas the action level corre-
sponding to the p95 intake of 210 g is only 1 ppm. Underestimating
consumption thus results in excessively high action levels and
associated higher actual risks. However, at the same time, it should
be remembered that the elaboration of reference doses embodies
several worst case assumptions and choices. It does not benefit
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any stakeholder if too much conservatism is built in, as this could
potentially lead to an unnecessarily high proportion of products
carrying a precautionary warning on the label and the risk of a
resulting loss of credibility (Cochrane et al., 2013). Of course, the
deterministic approach can be used as a basis for risk assessment,
although it cannot yield a quantitative output, as discussed else-
where (Madsen et al., 2009).
Probabilistic modelling (Method 2) can also be used to derive
action levels using food intake and minimum eliciting dose distri-
butions, as well as a certain accepted residual risk level as a start-
ing point. Probabilistic risk assessment modelling is illustrated
conceptually in Fig. 2 below.
In practice the program repeatedly samples the input distribu-
tions picking a value from each at random and builds a distribution
representing the probability of an allergic reaction given the values
and distributions of the specified variables. Probabilistic modelling
inherently accounts for the some of the uncertainties associated
with the input variables and reflects those in the probability
distribution for the output. It is important to note, however, that
probabilistic modelling cannot take into account factors such as
systematic bias in the selection of the challenge population, unless
they can be quantified. This approach is generally considered the
most appropriate approach for population risk assessment goals
(Spanjersberg et al., 2007, 2010; Madsen et al., 2009; Kruizinga
et al., 2008). Since its initial application to food allergen risk assess-
ment, it has been developed further with the introduction of
Bayesian inference of input variables (Rimbaud et al., 2010,
2013), coupling it with second-order Monte Carlo (MC2) simula-
tions to separately propagate the variability and uncertainty asso-
ciated with each of these variables.
Probabilistic risk assessment can also be used for instance to
validate elaborated action levels (for instance: have I chosen an
adequate consumption figure so that the residual risk at the action
level is 1% or below?) or for more precise quantification of the risk
of certain contamination and consumption scenarios. Another
application of probabilistic risk assessment is to quantify the effect
of adherence to a certain risk management regime or to investigate
the public health benefit of a more stringent cleaning regime.
5.2. Validation of action levels through probabilistic risk assessment
A critical question, particularly for regulators, concerns the risk
posed by consumption of more than one product contaminated
with the same allergen, and therefore to what extent such a possi-
bility needs to be considered in deciding on reference doses. As de-
scribed above, probabilistic modelling can be applied to estimate
the number of allergic individuals or the proportion of an (allergic)
population expected to suffer an allergic reaction due to a certain
concentration distribution of an allergen in food products (the
residual risk). As such, the approach is very suitable for assessing
whether the risk of allergic reactions for products containing aller-
genic residues at the action levels indeed remains around or below
the level of risk accepted. The expert group has used probabilistic
risk assessment to verify the conclusions about action levels in
relation to amount consumed in the peanut in bread example cited
earlier with the same result as the deterministic calculations. How-
ever, probabilistic modelling scores over such simple deterministic
calculations in the case of more complex scenarios such as assess-
ing the impact of the combined consumption during one meal of 2
Fig. 1. Elaboration of concentration action levels for ‘‘may contain’’ labelling.
Fig. 2. Probabilistic risk assessment (adapted from Spanjersberg et al., 2007).
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products that are both contaminated with the same allergen but at
different frequencies.
Two independent food intake scenarios were assessed: (1) a
meal with mashed potato and a sauce and (2) a meal with bread
and a chocolate spread. Each food intake scenario was assessed
for the risk arising from unintended peanut presence. The analyses
were conducted using food intake data from the US, Denmark and
the Netherlands. The outcomes of the impact analyses were simi-
lar, and for brevity, only Dutch data are presented and discussed
here.
The following consumption data were derived from the Dutch
Food Consumption survey (Hulshof et al., 2003) (see Table 3).
Action levels were calculated based on both the mean and the
p95 consumption data. The reference dose for peanut based on
the ED01 (0.2 mg) as given in Section 3.3 was used to determine
the action level. This resulted in the action levels below (Table 4).
Probabilistic risk assessment was done as described before
(Spanjersberg et al., 2007, 2010). All scenarios were run to calcu-
late the risk in the population of (peanut)-allergic users of the
product (i.e. prevalence of peanut allergy is not a variable). For
simplicity, we used point estimates to illustrate the scenarios
where a limited proportion of the products were contaminated,
although in practice, this would be a distribution with an associ-
ated uncertainty and variability. We did not have adequate data
to describe the occurrence of peanut cross-contact for the specific
products in question. Were such data available, it would be possi-
ble to perform a complete probabilistic analysis analogous to that
described by Rimbaud et al. (2013) for peanut contamination of
confectionery products in France. Such an approach could also be
used to derive action levels which would assure compliance with
defined reference doses according to specified criteria (e.g. 95%
assurance that the reference dose would be met).
For each product (combination) the risk was analysed in the fol-
lowing situations (contamination was assumed to be at the action
level):
– Product 1, all products contaminated with the allergen.
– Product 2, all products contaminated with the allergen.
– Product 1, 10% of the products contaminated with the allergen.
– Product 2, 10% of the products contaminated with the allergen.
– Product 1 and product 2 at the same eating occasion with each
of the products having a chance of 10% of being contaminated.
– Product 1 and product 2 at the same eating occasion with each
of the products having a chance of 100% of being contaminated.
The threshold distributions for the probabilistic modelling were
based on the work performed by the VITAL Scientific Expert Panel
and described in subSection 3.3, although only the dose distribu-
tions for adults were used. As the goal of the assessment was to
investigate whether the risks from combined exposure scenarios
would be significantly higher than the targeted residual risk of
1%, risk assessment based on action levels derived on the basis of
mean consumption can be considered as a worst case for this anal-
ysis as they are the higher ones. Only those results are shown. Fi-
nally, only the log logistic threshold distributions are shown as
they predicted the highest risk. The risk assessment results are
summarized in the Tables 5a and 5b below.
The results demonstrate clearly that only where all food prod-
ucts (so 100% of the batches produced) are assumed to be contam-
inated with peanut at the action level, is the residual risk slightly
higher than the 1% accepted residual risk. Where it is assumed that
only 10% of the batches are contaminated, fewer than 1% of pea-
nut-allergic consumers are predicted to be at risk of a reaction,
even if we assume that for the 10% of the batch that is contami-
nated the contamination at the maximum level (i.e. at the action
level), which still is a unrealistic worst case assumption. All other
risk estimates remained below the targeted 1% maximal residual
risk.
Table 3
Dutch Food Consumption Survey data for selected food.
Consumption of products in the Netherlands (excluding zero)
% Users of product in population Mean (g/meal occasion) P95 (g/meal occasion)
Mashed potato powder 2.3 5.1 9.4
Sauce from a package, including creamy sauces 15.6 72 200
Chocolate spread milk 3.3 43.1 180
Bread brown – wheat 62.8 118 210
Table 4
Action levels based on reference doses and calculated for mean and P95 consumption.
Action level based on
mean consumption
(mg/kg)











Residual risk from consumption of products contaminated with the same unintended
allergen (Illustration with mashed potato and sauce).






Mashed potato 100 0.82









a Proportion of peanut-allergic people eating the product combinations expected
to react.
Table 5b
Residual risk from consumption of products contaminated with the same unintended
allergen (Illustration with bread and chocolate spread).







Chocolate spread 100 0.72
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From these scenario analyses it can be safely concluded that the
risk from combined consumption of food products incidentally
contaminated with the same allergen will remain at or below the
maximum targeted residual risk (1% in this scenario analyses).
Combined consumption of food products contaminated with a
same allergen thus poses no significant additional health risk.
6. Conclusions
Risk assessment is at the heart of managing the risk from aller-
gens in the interests of all stakeholders. In recent years it has be-
come generally accepted that the principles and methodologies
developed for toxicological risk assessment can be applied to food
allergens as contaminants. While allergy being an immune re-
sponse means that risk can be considered from the perspective of
initiation of an immune response (sensitisation) as well as elicita-
tion (reaction), the specific risk assessment for food allergens ques-
tion focusses on the ability of (generally) low levels of allergenic
residues in manufactured foods to provoke reactions in sensitised
individuals. This risk can be quantified on the basis of data from
blinded diagnostic food challenges. The data used may have limita-
tions related to both the selection of participants and the investiga-
tion of reactivity. However, these limitations are outweighed by
the generation and availability of more robust data and modelling
approaches that do not rely upon low-dose extrapolations from
dose-distributions derived from clinical challenges with their
inherent uncertainties.
Understanding how to apply this risk assessment approach in
the food allergen stakeholder community is still challenging. Good
quality and amounts of data have become available for a range of
regulated allergens from food challenge studies, which have also
revealed that the range of MEDs spans at least 5–6 orders of mag-
nitude, making it difficult to derive a usable population NOAEL and
spurring the development of statistical models to analyse the data
meaningfully. Exposure assessment is a critical component of risk
assessment, but has not received as much attention. Exposure esti-
mates require not only good analytical tools to quantify allergens,
but also an understanding of the food consumption habits of peo-
ple with food allergies. Nevertheless general food consumption
data together with dose distribution data have proved particularly
valuable in combination with probabilistic risk assessment tech-
niques, which are able to integrate the uncertainties around many
of the inputs into a single one relating to the risk outcome. Appli-
cation of these models has provided useful insights which are not
only driving further refinements, but also generating testable
hypotheses. Results of model predictions have also thrown into
sharp focus the framing of the risk management questions, in par-
ticular those relating to the type of reaction that risk management
seeks to avoid.
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